Neptune Technologies & Bioressources Inc (NEPT.PH) Key Developments | Reuters.com
Edition:
United States

Neptune Technologies & Bioressources Inc (NEPT.PH)

NEPT.PH on Philadelphia Stock Exchange

1.14USD
8 Jun 2016
Change (% chg)

-- (--)
Prev Close
$1.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
790
52-wk High
$1.45
52-wk Low
$0.91

Latest Key Developments (Source: Significant Developments)

Neptune Technologies & Bioressources reports Q4 revenue of $10 mln
Wednesday, 25 May 2016 05:00pm EDT 

Neptune Technologies & Bioressources Inc : Neptune announces fourth quarter and fiscal year results . Neptune Sees FY 2017 revenue for Nutraceutical Segment to be greater than last 12 month fiscal 2016 revenue proforma of $41 million . Neptune Technologies & Bioressources Inc Qtrly revenues of $10.0 million, up 161% versus last year . In fiscal 2017, we expect significant growth in revenues and adjusted ebitda for nutraceutical segment .Net loss was $379,000 for current quarter, versus a net loss of $10.7 million in prior year.  Full Article

Acasti Pharma says Jan D'Alvise named as CEO
Thursday, 12 May 2016 08:08am EDT 

Acasti Pharma Inc : Says Jan D'Alvise appointed as president and chief executive officer effective June 1, 2016 .Jan D'Alvise appointed president & CEO of Acasti Pharma.  Full Article

Neptune Technologies & Bioressources Inc appoints new CFO
Wednesday, 5 Aug 2015 05:30pm EDT 

Neptune Technologies & Bioressources Inc:Announce the appointment of Mario Paradis as Chief Financial Officer (CFO), starting August 24, 2015.  Full Article

Neptune Technologies & Bioressources Inc gives Q2 2015 revenues guidance
Monday, 13 Jul 2015 05:00pm EDT 

Neptune Technologies & Bioressources Inc;:Expects Q2 2015revenues to be over $4.0 million, representing significant growth over Q1.  Full Article

NeuroBioPharm receives final court approval and completes arrangement with Neptune
Friday, 20 Feb 2015 07:30am EST 

NeuroBioPharm Inc:Says it has completed the previously announced plan of arrangement providing for the indirect acquisition by Neptune Technologies & Bioressources Inc of all of the issued and outstanding shares of NeuroBio and the issuance by Neptune of 116,714 class A shares to shareholders of NeuroBio.Says the Superior Court of Québec (Commercial Division) issued a final order on Feb. 16, , approving the Arrangement and all other conditions precedent for the completion of the Arrangement are satisfied.NeuroBio will apply to Canadian securities regulators to cease to be a reporting issuer in each of the provinces and territories of Canada in which it is currently a reporting issuer.NeuroBioPharm Inc, is a subsidiary of Neptune Technologies & Bioressources Inc.  Full Article

Neptune Technologies & Bioressources Inc appoints President & CEO
Friday, 21 Nov 2014 08:00am EST 

Neptune Technologies & Bioressources Inc:Appoints Jim Hamilton as President and Chief Executive Officer (CEO)of the company and a member of the Board, effective Feb. 2, 2015.  Full Article

Neptune Technologies & Bioressources Inc and BlueOcean sign licensing agreement
Monday, 20 Oct 2014 08:00am EDT 

Neptune Technologies & Bioressources Inc:Signs an exclusive world-wide, royalty-bearing, non-transferable, License Agreement (License) with BlueOcean Nutrascience Inc. (BlueOcean) under Neptune's composition and extraction patents covering production and sale of marine derived oil products containing phospholipids.The License allows BlueOcean and its shrimp joint venture affiliate to produce and sell shrimp oil products extracted from three species of North Atlantic cold water shrimp in nutraceutical, dietary ingredients, natural health products, functional food and food supplements markets.The medical food, drugs and drug product markets are not included.Commercial terms of the License include BlueOcean paying Neptune a minimum yearly cash royalty, and a royalty per unit of product sold.As well, an initial upfront payment will be payable at closing through the issuance of BlueOcean shares.Closing of the transaction is being done at arm's length and is subject to approval of the TSX Venture Exchange. No finder's fee is being paid in connection with this transaction.  Full Article

Neptune Technologies & Bioressources Inc gives Q3 2015 revenue guidance - Conference Call
Wednesday, 15 Oct 2014 09:00am EDT 

Neptune Technologies & Bioressources Inc:Says assuming ramp-up goes as currently planned, revenues for Q3 2015 should surpass C$4.4 million seen in Q3 2014.  Full Article

Neptune Technologies & Bioressources Inc announces normal course issuer bid
Wednesday, 15 Oct 2014 07:29am EDT 

Neptune Technologies & Bioressources Inc:Announced its intention to repurchase parts of its class A common shares issued and outstanding by way of a normal course issuer bid (NCIB).Says it may be allowed to repurchase up to the higher of 5 pct of its common shares issued and outstanding or 10 pct of its Public Float.  Full Article

Neptune Technologies & Bioressources Inc gives Q2 2014 revenue guidance - Conference Call
Thursday, 17 Jul 2014 09:00am EDT 

Neptune Technologies & Bioressources Inc:Expects revenues for Q2 2014 to remain at the same levels seen in Q1 2014.  Full Article